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Sudden cardiac death in the absence of structural heart
disease remains a tragic and often perplexing problem,
especially when it affects otherwise healthy young people.
Conditions resulting in sudden death, once labeled idio-
pathic ventricular ﬁbrillation, are now recognized as distinct
disorders of ion channel function. A recent addition to this
group of sudden death disorders is the short QT syndrome
(SQTS). Although it has been recognized for some time
that prolongation of cardiac repolarization is a substrate
for arrhythmias, the link between accelerated repolari-
zation and arrhythmia has only recently been established (1).
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The SQTS is a rare, sporadic, or autosomal dominant dis-
order characterized by markedly accelerated cardiac repo-
larization and manifested by dramatically shortened QT
interval, atrial and ventricular arrhythmias, and sudden
cardiac death. To date, mutations in potassium (KCNH2,
KCNQ1, KCNJ2) (2–4) and calcium channel subunit genes
(5,6) have been identiﬁed as causing SQTS. The clinical
manifestations of this disorder have been characterized in a
relatively small number of families and sporadic individuals,
given the recent identiﬁcation and rare nature of SQTS. In
this context, the report by Mazzanti et al. (7) in this issue of
the Journal, provides new and important knowledge with
regard to the natural history and the risk of life-threatening
events in SQTS. Moreover, the current report underscores
the limitations of our current strategies for risk stratiﬁcation
in this rare arrhythmia disorder.
The SQTS is a genetically heterogeneous disorder with
mutations described in 3 genes that encode for potassium
channels (KCNH2, KCNQ1, KCNJ2) (2–4). Mutations in
genes encoding L-type calcium channel subunits also cause
abbreviated QTc intervals but in some cases might represent
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the observation that most SQTS patients did not harbor a
mutation in any of the genes described so far in both the
current study and in previous reports (8). All potassium
channel mutations described to date represent gain-
of-function mutations in channels that mediate the plateau
and terminal phases of cardiac repolarization. The common
biophysical consequence of the SQTS-associated potassium
channel mutations is abnormal repolarizing current during
the early portion of the plateau phase. Under normal cir-
cumstances, repolarizing current during the plateau phase is
minimal, due to rectiﬁcation of inward potassium current
(IK)1 and IKr and the slow rate of IKs activation. By per-
turbing the gating properties that limit potassium ion efﬂux
during the plateau phase, cardiac repolarization is acceler-
ated, resulting in shortening of atrial and ventricular action
potential duration, arrhythmia susceptibility, and sudden
death. Because IK1, IKr, and IKs each contribute differen-
tially to cardiac repolarization, gene-speciﬁc mutations will
differentially inﬂuence repolarization and the susceptibility
to arrhythmia. Currently, detailed genotype-phenotype
information is limited by the rare nature of this disorder
but will certainly come into focus as more patients are
ascertained and carefully phenotyped.
Although the electrocardiogram is the diagnostic tool of
choice for SQTS, the precise values that deﬁne SQTS
remain to be determined unequivocally. This is due, in part,
to the considerable overlap between the QTc intervals of
affected and apparently healthy individuals. The QTc values
of 350 ms for men and 360 ms for women are derived
considering a cutoff value of 2 SDs from the mean value
obtained in a normal population (9). Although the QTc
of most SQTS patients falls below this cutoff value, a
large number of healthy individuals by deﬁnition also
fall below the value. However, a longitudinal study of
healthy individuals with a QTc <340 ms revealed no docu-
mented evidence of arrhythmias over an average follow-up
of 29 years (10). Other studies (11,12) also conﬁrm that a
short QT interval does not necessarily translate into an
increased risk of arrhythmias. By contrast, for individuals
that present with aborted cardiac arrest, syncope, or a family
history of cardiac arrest or SQTS, QTc values 2 SDs
from the mean achieve diagnostic value (13).
The risk of ventricular arrhythmias and sudden death is
remarkably high in SQTS, and the Mazzanti et al. study
(7) further corroborates observations from earlier studies
(8,14–16). Cardiac arrest was the most frequent presenting
symptom in the Mazzanti cohort (7), occurring in 40% of
the index cases. A modiﬁcation of the proposed diagnostic
criteria (13) was recently suggested to predict events in a
pediatric cohort of SQTS (14). Subjects with a modiﬁed
Gollob score of 3 corresponded to a low probability of
cardiac events (14). In the Mazzanti cohort (7), there was
not a relationship between a low risk score and a low
probability of cardiac events in that 5 of 8 subjects with a
score 3 experienced cardiac arrest. Unlike long QT
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life-threatening events, the degree of QT shortening does
not correlate with symptoms or outcome. In the Mazzanti et
al. study (7), the only predictor of subsequent cardiac arrest
was the ﬁnding of cardiac arrest at presentation. This
observation supports the recommendation for implantable
cardioverter-deﬁbrillator (ICD) insertion in SQTS subjects
that experience cardiac arrest.
Although not described in the current report, pharma-
cological therapy has clear theoretical promise for treatment
of SQTS. In theory, gain-of-function KCNH2 mutations
should be treatable with high-afﬁnity KCNH2 channel
blockers; however, the limited available evidence contradicts
this concept. The low-potency KCNH2 blocker d-sotalol
(IC50, approximately 100 mmol/l) failed to prolong QTc
when administered to 3 patients with the N588K mutation
(3). It should be noted, however, that mutations that reduce
KCNH2 inactivation also reduce the potency of KCNH2
channel blockers to variable degrees (17). Thus, the com-
bination of reduced afﬁnity of mutant KCNH2 channel
and the relatively low potency might explain the ineffec-
tiveness of d-sotalol to prolong the QT interval in these
patients. The high-potency KCNH2 channel blocker ibu-
tilide (IC50, approximately 40 nmol/l) failed to prolong
the QT interval in 2 members of the same SQTS family;
however, the genotype was not reported (18). Thus, the
effectiveness of high-potency (i.e., nanomolar potent)
KCNH2 channel blocking agents for treatment of SQTS
remains to be determined.
Of the pharmacological agents tested to date, quinidine
seems the most effective at prolonging the QT interval in
patients with SQTS. Quinidine prolonged the QT interval
and prevented ventricular ﬁbrillation induction in selected
SQTS subjects undergoing invasive study (18). Further
support for the effectiveness of quinidine was reported in a
long-term follow-up study from the European Short QT
registry (8). Quinidine is a complex drug, with multiple ion
channel-blocking effects, including blockade of INa, ICa, IKr,
IKs, and Ito. Although it is a nonselective blocker, it is a
more potent KCNH2 channel blocker than d-sotalol. The
effectiveness of quinidine for prolonging the QT interval
in patients with SQTS might be a consequence of more
potent KCNH2 channel blockade or a result of simulta-
neous block of multiple cardiac currents. Although ICD
insertion remains the primary therapeutic modality in sur-
vivors of cardiac arrest, quinidine might be beneﬁcial as
adjunct therapy in subjects with repeated appropriate ICD
discharges or as primary therapy for subjects in whom ICD
insertion is impractical.
In summary, our understanding of the natural history
of SQTS is evolving and will certainly improve as more
patients are ascertained. By virtue of the sheer number of
research subjects in this current report, Mazzanti et al. (7)
positively contribute to the advancement of our under-
standing of this rare arrhythmia disorder. We look forwardto longitudinal follow-up of this and other SQTS cohorts
(8) to realize an improved strategy for risk stratiﬁcation of
asymptomatic patients and thereby distinguish those who
might be predisposed to develop life-threatening events.
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